These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 17442267)

  • 1. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
    Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
    Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
    Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
    Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.
    Taymans JM; Vancraenenbroeck R; Ollikainen P; Beilina A; Lobbestael E; De Maeyer M; Baekelandt V; Cookson MR
    PLoS One; 2011; 6(8):e23207. PubMed ID: 21858031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
    Ito G; Okai T; Fujino G; Takeda K; Ichijo H; Katada T; Iwatsubo T
    Biochemistry; 2007 Feb; 46(5):1380-8. PubMed ID: 17260967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
    Liu Z; West AB
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
    Xiong Y; Dawson VL; Dawson TM
    Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
    Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
    Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The R1441C mutation alters the folding properties of the ROC domain of LRRK2.
    Li Y; Dunn L; Greggio E; Krumm B; Jackson GS; Cookson MR; Lewis PA; Deng J
    Biochim Biophys Acta; 2009 Dec; 1792(12):1194-7. PubMed ID: 19781641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
    Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GTPase function of LRRK2.
    Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1063-9. PubMed ID: 22988866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The unconventional G-protein cycle of LRRK2 and Roco proteins.
    Terheyden S; Nederveen-Schippers LM; Kortholt A
    Biochem Soc Trans; 2016 Dec; 44(6):1611-1616. PubMed ID: 27913669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROCO kinase activity is controlled by internal GTPase function.
    Weiss B
    Sci Signal; 2008 Jun; 1(23):pe27. PubMed ID: 18544747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.
    Huang X; Wu C; Park Y; Long X; Hoang QQ; Liao J
    FASEB J; 2019 Apr; 33(4):4814-4823. PubMed ID: 30592623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.
    Webber PJ; Smith AD; Sen S; Renfrow MB; Mobley JA; West AB
    J Mol Biol; 2011 Sep; 412(1):94-110. PubMed ID: 21806997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.